Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Warden Capital Hawkins Entrekin | “Alexandria is another – in attempting to catch a falling knife, I didn't quite time the bottom right, but I still believe we have a very attractive basis, and the stock looks even better today. ARE is the largest life sciences landlord in the US – this sector has struggled with a double whammy of a biotech bust and big oversupply (triple if you want to count WFH, though lab space wasn't hit quite as hard as normal office in this regard). I believe the stock is currently oversold – their portfolio is by far the highest quality with some truly top tier assets. The bio sector is coming back, and I believe strongly in its long term growth. In fact it began to recover somewhat in 2025, just take a look at the XBI. The stock market is a leading indicator, real estate leasing is very lagging, and we should see a turnaround in bio leasing fundamentals in the next year or two. ARE is trading at an ~10%+ cap rate today, which I believe falls to low 9s on future NOI declines – too cheap given the strong lease terms & asset quality. BSD Analysis: Alexandria Real Estate Equities is undergoing a strategic "asset recycling" phase in 2026, recently updating its FFO guidance to a range of $6.25 to $6.85 per share. The company's 2026 outlook is currently challenged by declining occupancy rates, though it remains the gold standard for life science and laboratory real estate. For the current year, the primary catalyst is the expected closure of $1 billion in asset dispositions, which will provide the liquidity needed to fund its robust development pipeline. Despite short-term pressures, the sector saw a 2.89% gain in early 2026, outperforming the broader market as tech-related selloffs drove rotation into high-quality REITs. Management's focus on "mega-campus" clusters in top-tier markets like Boston and San Francisco provides a significant competitive moat against traditional commercial office space. For value-oriented investors, the current discount to historical multiples offers an entry point into a REIT with a mission-critical tenant base and a proven long-term track record of dividend growth.” | BULL | Q4 2025 Feb 2, 2026 | View Pitch |
Davis Real Estate Fund Andrew A. Davis | “We have spoken about this REIT many times in prior investor letters, most often to describe how it has buoyed fund performance. We can't do that today. Half of Alexandria's market value evaporated during the year, an outcome reminiscent of the Great Financial Crisis. That follows on poor performance during 2024 and 2023. In a very real sense, Alexandria's trajectory, at least in terms of its relevance to DREF's benchmark, followed an inverse path to Welltower. In 2023 Alexandria was the seventh largest company in the index, just slightly smaller than Welltower. Today it is the forty-second largest constituent representing just 57 basis points of our benchmark. And because Alexandria has been getting smaller over the years, passive investment funds have been rebalancing out of it, putting selling pressure on its share price. During Alexandria's third quarter earnings call it became clear that the company expected positive inflection to be more likely a three-year proposition, perhaps even a bit longer. Making matters worse, Alexandria's considerable development funding plan partly depends on leasing success in the core portfolio. If leasing velocity slows materially, as appears almost certain, the company needs to source capital from other areas. At its annual investor day this past December, Alexandria announced it would accelerate a non-core asset disposition program and cut the dividend, both of which materially alter the timing and scale of cash flows. Needless to say, the negative stock price reaction for Alexandria during the fourth quarter of 2025 was swift and significant. In all respects it looks like an overreaction, placing at a historic discount what we view as one of the best real estate businesses in the country. Unlike during the Great Financial Crisis, when the company's balance sheet was stretched, today it is investment grade-rated with what we consider one of the most well-built balance sheets in the whole of our investment universe. Alexandria has all the markings of a quality company navigating a cyclical downturn but has ended up being priced like a distressed company facing mounting structural headwinds. :contentReference[oaicite:1]{index=1} BSD Analysis: Alexandria Real Estate Equities remains the gold standard in the life science real estate niche, focusing on its high-demand Megacampus ecosystems in top-tier innovation clusters. Despite facing near-term headwinds from market sentiment and legal filings, the company's operational fundamentals remain robust with a high-quality tenant base comprised of the world's leading pharmaceutical and biotech firms. Alexandria's portfolio of laboratory and specialized manufacturing space is largely insulated from the broader office downturn, as the nature of research requires physical presence and specialized infrastructure. The company has proactively managed its balance sheet through strategic debt tender offers, ensuring it has the liquidity to continue developing its significant pipeline. While the stock currently trades at a defensive valuation, its five percent dividend yield and essential role in the biotech ecosystem provide a solid foundation for long-term total returns.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
The Gabelli ABC Fund Mario J. Gabelli, CFA, Willis Brucker | “ALLETE Inc. is a utility company serving customers in Wisconsin and Minnesota. On May 6, 2024, GIP and CPP agreed to acquire ALLETE for $67.00 per share in cash. After a lengthy review, the Minnesota Public Utilities Commission approved the transaction on October 3, 2025. The deal was completed on December 15 following the issuance of the written order from the Minnesota Public Utilities Commission. We view the successful regulatory approval as validation of the company's stable regulated utility franchise. BSD Analysis: ALLETE is regulated utility infrastructure with a renewable tilt that the market treats like generic small-cap power. Earnings are driven by rate-base growth and allowed returns, not demand heroics. Investors worry about capital intensity and financing costs and miss the visibility embedded in regulated recovery frameworks. Renewable development adds long-duration optionality without abandoning core utility math. Political noise exists but doesn't change asset indispensability. Balance sheet management is conservative relative to growth ambitions. This is slow, predictable compounding tied to wires and wind, not headlines.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Diamond Hill Small-Mid Cap Strategy Anthony Philipp, Chris Welch | “We initiated a position in Alexandria Real Estate Equities, the largest owner of US life-sciences real estate concentrated in major biotech research clusters. The sector has been pressured by higher rates, lower venture capital funding, regulatory pressure and overbuilding. The company is working through a poorly timed development pipeline that reduced earnings and led to a dividend cut. After several years of underperformance, shares are deeply discounted despite a solid balance sheet and high-quality portfolio. BSD Analysis: Alexandria Real Estate Equities remains the gold standard for life science real estate, maintaining a dominant presence in top-tier cluster markets like Boston, San Francisco, and San Diego. Despite broader headwinds in the commercial office sector, Alexandria's mission-critical laboratory space continues to see sustained demand from major pharmaceutical and biotech tenants. The 2026 strategy is centered on a major asset recycling program, where the company is divesting non-core properties to fund the development of its high-demand mega-campus projects. While rising vacancy rates in newer lab builds have been a point of concern for the industry, Alexandria's high-quality, long-term lease structures and creditworthy tenant base provide a significant buffer. The company is also seeing a tailwind from the massive influx of capital into GLP-1 and immunology research, which requires specialized infrastructure.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Diamond Hill Small Cap Fund Aaron Monroe | “We initiated a position in Alexandria Real Estate Equities as the sector has been under pressure from higher interest rates, lower venture capital funding, regulatory pressure and overbuilding of new lab space. The company is working through a large, poorly timed development pipeline that reduced earnings and led to a dividend cut. After several years of underperformance, shares are deeply discounted despite a solid balance sheet and well-located portfolio. BSD Analysis: Alexandria Real Estate Equities remains the gold standard for life science real estate, maintaining a dominant presence in top-tier "cluster" markets like Boston, San Francisco, and San Diego. Despite broader headwinds in the commercial office sector, Alexandria's mission-critical laboratory space continues to see sustained demand from major pharmaceutical and biotech tenants. The 2026 strategy is centered on a major asset recycling program, where the company is divesting non-core properties to fund the development of its high-demand mega-campus projects. While rising vacancy rates in newer lab builds have been a point of concern for the industry, Alexandria's high-quality, long-term lease structures and creditworthy tenant base provide a significant buffer. The company is also seeing a tailwind from the massive influx of capital into GLP-1 and immunology research, which requires specialized infrastructure that only Alexandria can provide at scale. For income investors, the REIT's consistent dividend growth and fortress balance sheet offer a compelling combination of safety and long-term upside.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
